TW9

Overview

TW9 is a potent dual inhibitor simultaneously targeting BET and HDAC proteins with K D s of 0.069 μM, 0.231 μM for BRD4(1), BRD4(2), and an IC 50 of 0.29 μM for HDAC1 , respectively. TW9 is a newly generated adduct of the BET inhibitor (+)-JQ1 ( HY-13030 ) and class I HDAC inhibitor CI994 ( HY-50934 ). TW9 shows high potency in suppressing tumor growth in pancreatic ductal adenocarcinoma (PDAC). TW9 improves the efficacy of the chemotherapeutic agent Gemcitabine ( HY-17026 ).

Application

Products | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Epigenetic Reader Domain | Products > Signaling Pathways > HDAC

Product Information

• Catalog No.: HY-155222
• CAS No.: 2614417-90-0
• Molecular Formula: C32H28ClN7O2S
• Molecular Weight: 610.13
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source